Acne Treatment — Procedure Guide, Recovery & Risks | MyMedicPlus

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit — the hair follicle and associated sebaceous gland — affecting 80-90% of adolescents and persisting into adulthood in 25-30% of patients. It is the most common skin condition presenting to dermatologists worldwide. Acne arises from four interacting pathogenic mechanisms: excess sebum production driven by androgens acting on sebaceous glands, abnormal follicular hyperkeratinisation leading to comedone formation, colonisation of the follicle by Cutibacterium acnes (formerly Propionibacterium acnes), and subsequent innate immune-mediated inflammation triggering papules, pustules, nodules, and cysts. Treatment is targeted at one or more of these pathogenic pathways. The spectrum of treatment options spans topical agents (retinoids, benzoyl peroxide, antibiotics, azelaic acid), systemic agents (oral antibiotics, combined oral contraceptive pill, spironolactone in women, and oral isotretinoin), and procedural interventions (chemical peels, laser and light-based therapies, and physical extraction). Selecting the appropriate treatment ladder depends on acne severity, subtype, psychosocial impact, patient age and sex, and prior treatment history. Long-term management focuses on maintenance therapy and prevention of permanent scarring. Combination therapy targeting multiple pathogenic pathways simultaneously achieves faster, more complete responses and reduces the emergence of antibiotic-resistant Cutibacterium acnes strains that have become an increasing global concern.

Treatment is indicated for all grades of acne causing cosmetic concern, psychological distress, or carrying a significant risk of permanent scarring. Patients with mild comedonal acne (primarily open and closed comedones with few inflammatory lesions) benefit from topical retinoids alone, which normalise follicular keratinisation and prevent new comedone formation. Moderate acne — a mixture of comedones, papules, and pustules affecting the face or trunk — requires combination therapy including topical retinoid plus benzoyl peroxide with or without a short-course oral antibiotic (limited to 3 months to minimise antibiotic resistance). Severe or nodulo-cystic acne, acne causing scarring, acne refractory to two prior antibiotic courses, or acne with severe psychological impact warrants oral isotretinoin therapy, which is the only treatment that addresses all four pathogenic mechanisms simultaneously and can induce prolonged remission or cure. Women with acne associated with hormonal features — perimenstrual flares, jaw and chin distribution, or hyperandrogenism markers — benefit from combined oral contraceptive pill (COCP) or low-dose spironolactone as adjunctive systemic therapy.

Mild comedonal acne: first-line treatment is topical adapalene 0.1% gel or tretinoin 0.025-0.05% cream (retinoid), applied to the entire affected area — not spot-applied — each evening after cleansing, combined with topical benzoyl peroxide 5% gel applied in the morning to prevent emergence of antibiotic-resistant Cutibacterium acnes. This combination is continued for a minimum of 12 weeks before reassessment. Moderate inflammatory acne: topical retinoid plus benzoyl peroxide combination is maintained as the backbone. Oral lymecycline 408 mg once daily or doxycycline 100 mg once daily is added for a maximum 12-week course and then stopped, with the topical regimen continued as maintenance. Oral antibiotics are never used alone (always with topical retinoid and benzoyl peroxide) to limit resistance induction. Severe or refractory acne requiring oral isotretinoin: treatment is initiated by a dermatologist after mandatory pregnancy exclusion in women of childbearing potential. Starting dose is 0.3-0.5 mg/kg/day, titrated to a cumulative target dose of 120-150 mg/kg. Monthly monitoring includes full blood count, liver function tests, fasting lipids, and pregnancy test. Treatment duration is typically 16-24 weeks. Female hormonal acne: COCP (co-cyprindiol, Yasmin, or Gedarel) or spironolactone 50-100 mg/day is prescribed alongside topical maintenance therapy. Treatment response is assessed at 12 weeks; if insufficient, the regimen is escalated according to evidence-based guidelines from NICE, BAD, or AAD.

Oral isotretinoin achieves long-term remission or effective cure in 60-70% of patients after a single treatment course at adequate cumulative dosing, with many patients requiring no further acne treatment for years. For those who relapse, a second course is effective in the majority. Topical adapalene plus benzoyl peroxide combination therapy reduces inflammatory lesion counts by 60-70% at 12 weeks in moderate acne and is the most evidence-based topical regimen for maintenance. Combined oral contraceptive pill reduces inflammatory and non-inflammatory acne lesions by 50-60% in women with hormonal acne, with additional benefits for perimenstrual flares and associated dysmenorrhoea. Procedural interventions including chemical peels (glycolic acid 20-70%, salicylic acid 20-30%) improve mild-to-moderate acne, reduce post-inflammatory hyperpigmentation, and improve texture. Physical extraction by trained clinicians under sterile conditions immediately clears open and closed comedones. Early and effective treatment prevents the permanent scarring — ice-pick, boxcar, and rolling scars — that occurs in moderate-to-severe untreated acne and is much more difficult to treat than the acne itself.

Topical retinoids cause an initial purging period in the first 2-4 weeks where acne may temporarily worsen as blocked follicles expel their contents; this is expected and not a reason to discontinue. Ongoing side effects include skin dryness, redness, scaling, and photosensitivity requiring daily broad-spectrum SPF 50+ sunscreen; these effects are dose-dependent and reduce after 6-8 weeks of adaptation. Oral isotretinoin has significant teratogenicity — it is absolutely contraindicated in pregnancy and causes major congenital malformations in over 25% of exposed pregnancies. Women of childbearing age must use dual contraception and enrol in a pregnancy prevention programme (UK: iPLEDGE-equivalent scheme) with monthly pregnancy testing. Systemic side effects include mucocutaneous dryness (universal — dry lips, nasal mucosa, conjunctiva), transient elevated liver enzymes in 5-10%, hypertriglyceridaemia in 25-40%, and possible mood changes. An association with inflammatory bowel disease and depression has been debated; current evidence does not establish causality but patients with pre-existing mood disorder require monitoring. Oral antibiotics used long-term promote C. acnes and gut microbiome resistance; courses must be strictly limited to 3 months maximum.

Topical treatments require 8-12 weeks for initial clinical response and 3-6 months for maximum benefit; photosensitivity during treatment mandates daily SPF 50+ broad-spectrum sunscreen on all treated areas, including on non-sunny days. Oral antibiotic courses must not exceed 12 weeks; maintenance after stopping antibiotics uses topical retinoid plus benzoyl peroxide to prevent relapse and maintain the achieved improvement. During isotretinoin therapy, patients must attend monthly clinical reviews with blood monitoring and, in women, mandatory pregnancy testing. Skin is highly photosensitive during treatment; sun avoidance and high-factor sunscreen are essential throughout. After completing isotretinoin, maintenance topical therapy (retinoid ± azelaic acid) is continued for at least 6-12 months to prevent relapse. Post-acne scarring is managed with resurfacing procedures — fractional CO2 laser, subcision, dermal fillers, or microneedling — typically beginning 6-12 months after successful acne control when the skin is in a stable, non-inflamed state. Long-term follow-up ensures early detection and treatment of any recurrence.